Postresection stage grouping in carcinoma of the lung.
Postresection stage grouping in carcinoma of the lung.
复制标题
肺癌切除后分期分组。
DOI：
--
复制
发表时间：
1977
期刊：
影响因子：
--
通讯作者：
Keehn Rj
中科院分区：
文献类型：
--
作者：
Shields Tw;Keehn Rj
肺癌术后治疗分类和分期系统在一系列403名患者中进行了评估，这些患者接受了由退伍军人管理局外科辅助小组进行的完整的前瞻性随机辅助癌症化疗试验。美国癌症分期和最终结果报告联合委员会建议的T、N和M分类得到支持。然而，委员会建议的阶段分组未能充分区分不同的预测群体。这似乎更好地完成了放射治疗肿瘤学小组建议的分期分组修改。在后一种方案中，术后治疗I期疾病的患者的五年存活率为40.9%，II期患者为26.2%，III期患者为10.5%。在联合委员会分类中，这些存活率分别为30.8%、25.5%和10.5%。此外，还对18例未分化小细胞癌患者进行了评估。有3例周围性小病变且无转移性淋巴结转移的患者长期存活，这支持了切除这些特殊病变仍然是首选治疗的观点。
The postsurgical treatment classification and staging system for carcinoma of the lung has been evaluated in a series of 403 patients admitted to a completed prospective randomized adjuvant cancer chemotherapy trial conducted by the Veterans Administration Surgical Adjuvant Group. The proposed T, N and M classification suggested by the American Joint Committee for Cancer Staging and End Results Reporting is supported. However, the stage groupings as suggested by the Committee fails to separate adequately the various prognostic groups. This appears to be better accomplished by the stage grouping modification suggested by the Radiation Therapy Oncology Group. In the latter schema, the five year survival rate of patients with postsurgical treatment Stage I disease is 40.9 per cent; Stage II, 26.2 per cent, and Stage III, 10.5 per cent. In the Joint Committee classification, these survival rates are 30.8 per cent, 25.5 per cent and 10.5 per cent, respectively. In addition, 18 patients with undifferentiated small cell carcinoma were also evaluated. The long term survival of three of sixe patients with small peripheral lesions without metastatic lymph node involvement supports the opinion that resection of these specific lesions continues to be the treatment of choice.